Published in Gastroenterology on March 04, 2008
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells (2009) 1.89
Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology (2009) 1.53
Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology (2011) 1.39
LGR5 is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines. PLoS One (2011) 1.36
Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer (2010) 1.31
Genomic analyses of musashi1 downstream targets show a strong association with cancer-related processes. J Biol Chem (2009) 1.29
The spatial distribution of LGR5+ cells correlates with gastric cancer progression. PLoS One (2012) 1.26
Colon cancer stem cells: implications in carcinogenesis. Front Biosci (Landmark Ed) (2011) 1.23
RNA-binding protein Musashi1 modulates glioma cell growth through the post-transcriptional regulation of Notch and PI3 kinase/Akt signaling pathways. PLoS One (2012) 1.14
Asymmetric cell division of stem and progenitor cells during homeostasis and cancer. Cell Mol Life Sci (2013) 1.11
The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells. J Cell Mol Med (2010) 1.08
Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. J Cell Mol Med (2013) 1.06
Developmental timing of mRNA translation--integration of distinct regulatory elements. Mol Reprod Dev (2010) 1.06
Musashi1 modulates cell proliferation genes in the medulloblastoma cell line Daoy. BMC Cancer (2008) 1.04
Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest (2015) 1.03
Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression. Oncotarget (2015) 1.02
The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol Cancer Res (2012) 1.02
Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis (2009) 1.00
Context-dependent regulation of Musashi-mediated mRNA translation and cell cycle regulation. Cell Cycle (2011) 0.98
The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. Am J Pathol (2012) 0.98
Colon cancer stem cells. Gastrointest Cancer Res (2010) 0.98
Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int (2013) 0.97
Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol (2009) 0.96
Transformation of the intestinal epithelium by the MSI2 RNA-binding protein. Nat Commun (2015) 0.93
Musashi expression in β-cells coordinates insulin expression, apoptosis and proliferation in response to endoplasmic reticulum stress in diabetes. Cell Death Dis (2011) 0.92
Novel double-negative feedback loop between adenomatous polyposis coli and Musashi1 in colon epithelia. J Biol Chem (2011) 0.92
A comprehensive in silico expression analysis of RNA binding proteins in normal and tumor tissue: Identification of potential players in tumor formation. RNA Biol (2009) 0.91
The impact of post-transcriptional regulation in the p53 network. Brief Funct Genomics (2012) 0.89
Non-invasive in vivo imaging of tumor-associated CD133/prominin. PLoS One (2010) 0.88
Musashi1 as a potential therapeutic target and diagnostic marker for lung cancer. Oncotarget (2013) 0.87
Expression and significance of Musashi-1 in gastric cancer and precancerous lesions. World J Gastroenterol (2013) 0.85
Role of RNA-Binding Proteins in Colorectal Carcinogenesis. Curr Colorectal Cancer Rep (2010) 0.85
A Mouse Model of Targeted Musashi1 Expression in Whole Intestinal Epithelium Suggests Regulatory Roles in Cell Cycle and Stemness. Stem Cells (2015) 0.83
Natural product (-)-gossypol inhibits colon cancer cell growth by targeting RNA-binding protein Musashi-1. Mol Oncol (2015) 0.83
Allosteric inhibition of a stem cell RNA-binding protein by an intermediary metabolite. Elife (2014) 0.83
Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. Carcinogenesis (2013) 0.82
Autoregulation of Musashi1 mRNA translation during Xenopus oocyte maturation. Mol Reprod Dev (2012) 0.82
RNA binding protein-mediated post-transcriptional gene regulation in medulloblastoma. Mol Cells (2014) 0.82
Identification of a novel intronic enhancer responsible for the transcriptional regulation of musashi1 in neural stem/progenitor cells. Mol Brain (2011) 0.81
A 1536-well fluorescence polarization assay to screen for modulators of the MUSASHI family of RNA-binding proteins. Comb Chem High Throughput Screen (2014) 0.81
Musashi-1 suppresses expression of Paneth cell-specific genes in human intestinal epithelial cells. J Gastroenterol (2009) 0.81
Endometrial cells get side-tracked: side population cells promote epithelial-mesenchymal transition in endometrial carcinoma. Am J Pathol (2009) 0.80
Drosophila Rbp6 is an orthologue of vertebrate Msi-1 and Msi-2, but does not function redundantly with dMsi to regulate germline stem cell behaviour. PLoS One (2012) 0.79
RNA-Binding Protein Musashi1 Is a Central Regulator of Adhesion Pathways in Glioblastoma. Mol Cell Biol (2015) 0.79
Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A (2016) 0.78
Musashi2 as a novel predictive biomarker for liver metastasis and poor prognosis in colorectal cancer. Cancer Med (2016) 0.77
Prognostic significance of neural stem cell markers, Nestin and Musashi-1, in oral squamous cell carcinoma: expression pattern of Nestin in the precancerous stages of oral squamous epithelium. Clin Oral Investig (2014) 0.77
Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma. Oncotarget (2016) 0.77
Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis. Biomed Res Int (2015) 0.77
Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury. PLoS One (2015) 0.76
The RNA-Binding Protein Musashi1: A Major Player in Intestinal Epithelium Renewal and Colon Cancer Development. Curr Colorectal Cancer Rep (2012) 0.76
Musashi1 Impacts Radio-Resistance in Glioblastoma by Controlling DNA-Protein Kinase Catalytic Subunit. Am J Pathol (2016) 0.76
Suppression of intestinal tumorigenesis in Apc mutant mice by Musashi-1 deletion. J Cell Sci (2017) 0.75
Neural stem and progenitor cell fate transition requires regulation of Musashi1 function. BMC Dev Biol (2015) 0.75
hnRNP C1/C2 and Pur-beta proteins mediate induction of senescence by oligonucleotides homologous to the telomere overhang. Onco Targets Ther (2013) 0.75
Overexpression of Musashi-1 protein is associated with progression and poor prognosis of gastric cancer. Oncol Lett (2017) 0.75
Functional Integration of mRNA Translational Control Programs. Biomolecules (2015) 0.75
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Genomics and drug response. N Engl J Med (2011) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
A high-resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genet (2006) 3.24
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost (2004) 2.64
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell (2003) 2.46
Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A (2004) 2.37
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost (2005) 2.25
Sargramostim for active Crohn's disease. N Engl J Med (2005) 2.24
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther (2009) 2.10
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs (2005) 2.09
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.95
Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J Clin Invest (2014) 1.90
Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med (2013) 1.89
Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells (2009) 1.89
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther (2006) 1.82
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol (2008) 1.81
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet (2005) 1.75
DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res (2011) 1.73
Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther (2006) 1.63
A nomenclature for intestinal in vitro cultures. Am J Physiol Gastrointest Liver Physiol (2012) 1.61
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest (2004) 1.59
Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology (2010) 1.57
Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology (2004) 1.56
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol (1985) (2003) 1.55
Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology (2009) 1.53
Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol (2005) 1.52
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res (2008) 1.50
Expression of the regenerating gene family in inflammatory bowel disease mucosa: Reg Ialpha upregulation, processing, and antiapoptotic activity. J Investig Med (2002) 1.49
Pharmacogenomic discovery approaches: will the real genes please stand up? J Clin Oncol (2005) 1.49
Helicobacter Pylori's plasticity zones are novel transposable elements. PLoS One (2009) 1.48
wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. Nucleic Acids Res (2008) 1.48
Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol (2007) 1.46
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer (2003) 1.41
Delayed hepatocellular mitotic progression and impaired liver regeneration in early growth response-1-deficient mice. J Biol Chem (2004) 1.40
Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology (2011) 1.39
Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther (2007) 1.38
Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502d7 that demethylates codeine to morphine", J Biol Chem 279: 27383-27389. Drug Metab Dispos (2005) 1.38
Translational inhibition of colonic epithelial heat shock proteins by IFN-gamma and TNF-alpha in intestinal inflammation. Gastroenterology (2007) 1.36
CANDID: a flexible method for prioritizing candidate genes for complex human traits. Genet Epidemiol (2008) 1.36
Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer (2003) 1.36
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics (2011) 1.34
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics (2008) 1.33
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol (2009) 1.32
Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res (2006) 1.31
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res (2002) 1.31
Functional antagonism between RNA binding proteins HuR and CUGBP2 determines the fate of COX-2 mRNA translation. Gastroenterology (2006) 1.31
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. Cancer Res (2008) 1.29
Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology (2006) 1.28
Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis (2008) 1.28
Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am J Physiol Gastrointest Liver Physiol (2010) 1.28
Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet (2006) 1.28
Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum (2006) 1.27
PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One (2012) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics (2012) 1.23
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat (2012) 1.23